In the EU, REMICADE is also indicated for the treatment of AS in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. REMICADE is also approved for the treatment of active and progressive PsA in adults when the response to previous disease modifying anti-rheumatic drug therapy has been inadequate. REMICADE should be administered in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. REMICADE is also approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or PUVA (psoralen plus ultraviolet A light).
In February 2006, REMICADE was approved in the EU for the treatment of
moderately to severely active UC in patients who have had an inadequate
response to conventional therapy, including corticosteroids and 6-MP or
azathioprine, or who are intolerant to or have medical contraindications
for such therapies. This approval made REMICADE the first and only biologic
therapy approved to treat moderate to severe UC in the EU. In May 2007,
REMICADE was indicated for the treatment of severe, active Crohn's disease,
in pediatric patients aged 6 to 17 years, who have not responded to
conventional therapy including a corticoste
|SOURCE Centocor, Inc.|
Copyright©2007 PR Newswire.
All rights reserved